- Home
- Publications
- Publication Search
- Publication Details
Title
New Pharmacological Approaches to Target PCSK9
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 22, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-04
DOI
10.1007/s11883-020-00847-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
- (2020) Peter G. Chandler et al. Cells
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel strategies to target PCSK9: beyond monoclonal antibodies
- (2019) Nabil G Seidah et al. CARDIOVASCULAR RESEARCH
- LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY
- (2019) Evan A. Stein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cholesterol metabolism, pancreatic β-cell function and diabetes
- (2019) Carla Perego et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
- (2019) E. Stein et al. ATHEROSCLEROSIS
- Inclisiran Durably Lowers Ldl-C And Pcsk9 Expression In Subjects With Homozygous Familial Hypercholesterolaemia: The Orion-2 Pilot Study
- (2019) F. Raal et al. ATHEROSCLEROSIS
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
- (2019) Amir Abbas Momtazi-Borojeni et al. BMC Medicine
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
- (2018) Ye-Xuan Cao et al. DIABETES OBESITY & METABOLISM
- PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
- (2018) Lorenzo Da Dalt et al. EUROPEAN HEART JOURNAL
- Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
- (2018) Andrea Baragetti et al. PHARMACOLOGICAL RESEARCH
- Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
- (2018) Ryo Kawakami et al. PLoS One
- Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
- (2018) Michel Farnier et al. ATHEROSCLEROSIS
- RNA Therapeutics in Cardiovascular Precision Medicine
- (2018) Ageliki Laina et al. Frontiers in Physiology
- Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake
- (2018) Adri M. Galvan et al. JOURNAL OF LIPID RESEARCH
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antidrug Antibodies in Patients Treated with Alirocumab
- (2017) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
- (2017) Camilla Gustafsen et al. Nature Communications
- PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
- (2017) Andrea Baragetti et al. European Journal of Preventive Cardiology
- Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
- (2017) Nathanael G. Lintner et al. PLOS BIOLOGY
- Genetic Architecture of Familial Hypercholesterolaemia
- (2017) Mahtab Sharifi et al. Current Cardiology Reports
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia
- (2017) Michael J. Koren et al. JAMA Cardiology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- A Therapeutic Peptide Vaccine Against PCSK9
- (2017) Yajie Pan et al. Scientific Reports
- Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
- (2016) Peter H. Jones et al. AMERICAN JOURNAL OF CARDIOLOGY
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
- (2016) Giuseppe Danilo Norata et al. CARDIOVASCULAR RESEARCH
- Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells
- (2016) Derek T. Peters et al. DEVELOPMENT
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese
- (2015) Clara S. Tang et al. Nature Communications
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY
- (2014) Evan A. Stein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Antisense Oligonucleotide Therapies
- (2014) Kendall S. Frazier TOXICOLOGIC PATHOLOGY
- PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
- (2014) Giuseppe Danilo Norata et al. VASCULAR PHARMACOLOGY
- Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice 性别与西方饮食对CSK9基因缺陷的PC57BL/6老龄小鼠的脂质以及葡萄糖内稳态的不同影响
- (2014) Majambu Mbikay et al. Journal of Diabetes
- Targeting PCSK9 for Hypercholesterolemia
- (2013) Giuseppe Danilo Norata et al. Annual Review of Pharmacology and Toxicology
- New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
- (2013) Giuseppe Danilo Norata et al. EUROPEAN HEART JOURNAL
- Gene silencing approaches for the management of dyslipidaemia
- (2013) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Silencing disease genes in the laboratory and the clinic
- (2011) Jonathan K Watts et al. JOURNAL OF PATHOLOGY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition
- (2011) G. Tibolla et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles
- (2009) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- APCSK9Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
- (2008) Sekar Kathiresan NEW ENGLAND JOURNAL OF MEDICINE
- Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
- (2007) Yasuko Miyake et al. ATHEROSCLEROSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation